People: InMed Pharmaceuticals Inc (IN.CD)

IN.CD on Canadian Securities Exchange

0.17CAD
3 Jun 2015
Change (% chg)

$-0.00 (-2.94%)
Prev Close
$0.17
Open
$0.17
Day's High
$0.17
Day's Low
$0.16
Volume
23,000
Avg. Vol
347,285
52-wk High
$0.71
52-wk Low
$0.11

Search Stocks

Summary

Name Age Since Current Position

Craig Schneider

2012 President, Chief Executive Officer

Terese Gieselman

2011 Chief Financial Officer

Abo Mohammed

2015 Chief Medical Officer

Tarek Mansour

2015 Director

Kevin Puil

2015 Director

Stephen Tong

2013 Director

Biographies

Name Description

Craig Schneider

Mr. Craig Schneider has been appointed as President, Chief Executive Officer of Meridex Software Corp., effective 10 December 2012.

Terese Gieselman

Ms. Terese J. Gieselman serves as Chief Financial Officer of Meridex Software Corp., since June 27, 2011. Ms. Gieselman has had 23 years experience with junior mining and exploration companies listed on the Toronto Stock Exchange, TSX Venture Exchange, OTCBB, the Nasdaq Stock Market and Amex in the roles of chief financial officer. Ms. Gieselman has accumulated an experience background in corporate and financial reporting and compliance for Canada and the United States, including particularly relevant experience in financings, treasury and international corporate structures.

Abo Mohammed

Dr. Abo Mohammed, M.D., DPM, MFPM, is Chief Medical Officer of the Company. Prior to joining InMed Pharmaceuticals, Dr. Mohammed served as associate medical director at GW Pharmaceuticals, a United Kingdom-based pharmaceutical company specializing in the development of cannabinoid-based prescription medicines. In this role, and others at GW Pharmaceuticals, Dr. Mohammed was involved in the advanced delivery of core clinical research, and was involved in key decision making regarding research and development, and product commercialization. He played a leading role in GW Pharmaceuticals' pharma-covigilance team, where his responsibilities included handling of the company's drug safety data from both clinical trials and postmarketing sources, and general management of safety signals including investigations, reviews and reporting. He is also a consultant to the Nigerian regulatory authority (National Agency for Food and Drug Administration and Control) in the areas of pharma-covigilance, postmarketing surveillance and clinical trials. Prior to joining GW Pharmaceuticals, Dr. Mohammed was with PPD (Pharmaceutical Product Development), a leading global contract research organization providing drug discovery, development, life cycle management and laboratory services. Dr. Mohammed also served as CMO/clinical director in various public health care establishments in Africa from 1996 to November, 2010. Dr. Mohammed received his MD at Ahmadu Bello University, Zaria, Nigeria, followed by an MSc in orthopedics at University College London. Dr. Mohammed achieved a DipPharMed in pharmaceutical medicine at the University of Wales in Cardiff. He is a member of the faculty of pharmaceutical medicine at the Royal College of Physicians of England, the British Association of Pharmaceutical Physicians and the International Society for Pharma-covigilance.

Tarek Mansour

Dr. Tarek Mansour, Ph.D., is Director of the Company. Dr. Mansour was previously with Xenon Pharmaceuticals as its executive vice-president. He also held similar positions at Pfizer and Wyeth Pharmaceuticals, prior to founding Sabila Biosciences LLC, where he is currently the chief executive officer. Dr. Mansour's expertise spans multiple therapeutic areas including anti-infectives, oncology, inflammatory, metabolic, cardiovascular and pain. Under his leadership, several compounds have progressed to various stages of clinical evaluation including Food and Drug Administration approvals, and late-stage development. Amongst these candidates are Epivir, Zeffix, Troxatyl, Bosulif, Neratinib and PFE384. Dr. Mansour received a bachelor of science degree in chemistry from the American University of Beirut, Lebanon (1977), a master of science in chemistry from the University of Manchester Institute of Science and Technology, United Kingdom (1979), a PhD degree from the University of Missouri-Columbia, United States (1982), and a diploma in applied management from McGill University, Canada (1993). Following postdoctoral tenure at the University of Ottawa, Dr. Mansour moved to McGill University in 1985 as a research associate in the immunomedicinal chemistry chair.

Kevin Puil

Mr. Kevin Puil is Director of the Company. Mr. Puil is currently a managing partner at a private equity fund based in California. Prior to that, he held senior positions at several firms including Bolder Investment Partners in Vancouver (now Haywood Securities), where he was a partner and portfolio manager; and in San Francisco at Gissen & Associates as portfolio manager, and the Encompass Fund as senior analyst. He currently serves as a board director of two Toronto Stock Exchange companies. He holds a degree in economics from the University of Victoria in British Columbia and is a chartered financial analyst charterholder.

Stephen Tong

Mr. Stephen Tong has been appointed as Director of Meridex Software Corp., with effect from July 03, 2013. Mr. Tong has been a securities lawyer in Vancouver since 1999, and has served on the boards of numerous public and private companies in various industries.

Basic Compensation

Name Fiscal Year Total

Craig Schneider

--

Terese Gieselman

12,810

Abo Mohammed

--

Tarek Mansour

--

Kevin Puil

--

Stephen Tong

--
As Of  29 Jun 2012

Options Compensation

Search Stocks